Reuters logo
Cytokinetics says Lou Gehrig's drug fails mid-stage trial
April 25, 2014 / 11:53 AM / 3 years ago

Cytokinetics says Lou Gehrig's drug fails mid-stage trial

April 25 (Reuters) - Cytokinetics Inc said its experimental treatment for Lou Gehrig’s disease - a progressive neurodegenerative disorder - failed the main goal in a mid-stage trial.

The study tested the efficacy of the drug, tirasemtiv - one of the company’s lead compounds - against a placebo in 711 patients with amyotrophic lateral sclerosis (ALS).

The San Francisco-based company’s stock was halted before the bell on Friday. (Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below